The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1118
November 12, 2001
View Complete Issue         Table of Contents 2019 
Cardiovascular Safety of Cox-2 Inhibitors
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cardiovascular Safety of Cox-2 Inhibitors
November 12, 2001 (Issue: 1118)
Related Articles Since Publication Increasing use of rofecoxib (Vioxx) and celecoxib (Celebrex), both selective inhibitors of cyclooxygenase-2 (COX-2), for treatment of arthristis has been accompanied by concerns that they may increase risk of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cardiovascular Safety of Cox-2 Inhibitors
Article code: 1118a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.